TheraVida raises seed funding for urology research
TheraVida, a new biotech based in San Mateo, Calif., has raised seed funding from Sanderling Ventures, VentureWire reports (subscription required). The company, which doesn’t seem to have a Web site (a possible stub site is here), is researching possible drugs for urological problems.
According to VentureWire, the seed funding was less than $1 million, although the company may seek a larger first funding round by the end of the year. TheraVida has one employee, a former researcher at TheraVance.
Next Story: BackFence closes its gates
Previous Story: Roundup: Virtual sex bed suit, Geni, Gay.com, Netvibes, Helio and more
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.